{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T16:47:01Z","timestamp":1794934021702,"version":"4.9.1"},"reference-count":52,"publisher":"American Society of Hematology","issue":"10","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,5,24]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a clinically aggressive blood cancer, often involving the skin, bone marrow, lymph nodes, and central nervous system (CNS) in 20% to 30% of patients. Despite significant progress in CD123- and BCL-2\u2013targeted therapy, most patients are not cured without hematopoietic stem cell transplant (HSCT), and CNS relapses occur quite frequently. Combination approaches with targeted and chemotherapy agents plus incorporation of prophylactic CNS-directed therapy are urgently needed. In this setting, we sought to analyze outcomes using the cytotoxic chemotherapy backbone regimen hyperfractionated cyclophosphamide, vincristine, adriamycin, and dexamethasone (HCVAD). We conducted a retrospective analysis of patients with BPDCN (n = 100), evaluating complete remission (CR) and median overall survival (OS) among 3 groups: those who received frontline HCVAD-based therapy (n = 35), SL-401 (n = 37), or other regimens (n\u00a0=\u00a028). HCVAD-based regimens yielded higher CR (80% vs 59% vs 43%; P = .01). There was no significant difference in OS (28.3 vs 13.7 vs 22.8 months; P = .41) or remission duration probability among treatment groups (38.6 vs not reached vs 10.2 months; P = .24). HSCT was performed in 51% vs 49% vs 38%, respectively (P = .455). These results suggest a continued important role for HCVAD-based chemotherapy in BPDCN, even in the modern targeted-therapy era, with high CR rates in the frontline setting. Further studies must establish the clinical activity, feasibility, and safety of doublet\/triplet combinations of targeted therapies plus cytotoxic agents and the addition of CNS prophylaxis, with the ultimate goal of durable long-term remission for patients with BPDCN.<\/jats:p>","DOI":"10.1182\/bloodadvances.2021006645","type":"journal-article","created":{"date-parts":[[2022,1,21]],"date-time":"2022-01-21T15:57:58Z","timestamp":1642780678000},"page":"3027-3035","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":49,"title":["Characteristics and outcomes of patients with blastic plasmacytoid dendritic cell neoplasm treated with frontline HCVAD"],"prefix":"10.1182","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1670-6513","authenticated-orcid":false,"given":"Naveen","family":"Pemmaraju","sequence":"first","affiliation":[{"name":"Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9123-1781","authenticated-orcid":false,"given":"Nathaniel R.","family":"Wilson","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, The University of Texas McGovern Medical School, Houston, TX;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillermo","family":"Garcia-Manero","sequence":"additional","affiliation":[{"name":"Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9140-0610","authenticated-orcid":false,"given":"Koji","family":"Sasaki","sequence":"additional","affiliation":[{"name":"Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2621-3584","authenticated-orcid":false,"given":"Joseph D.","family":"Khoury","sequence":"additional","affiliation":[{"name":"Department of Hematopathology, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nitin","family":"Jain","sequence":"additional","affiliation":[{"name":"Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gautam","family":"Borthakur","sequence":"additional","affiliation":[{"name":"Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farhad","family":"Ravandi","sequence":"additional","affiliation":[{"name":"Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7103-373X","authenticated-orcid":false,"given":"Naval","family":"Daver","sequence":"additional","affiliation":[{"name":"Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tapan","family":"Kadia","sequence":"additional","affiliation":[{"name":"Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9003-0390","authenticated-orcid":false,"given":"Courtney","family":"DiNardo","sequence":"additional","affiliation":[{"name":"Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elias","family":"Jabbour","sequence":"additional","affiliation":[{"name":"Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sherry","family":"Pierce","sequence":"additional","affiliation":[{"name":"Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muzaffar","family":"Qazilbash","sequence":"additional","affiliation":[{"name":"Department of Stem Cell Transplantation, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9347-2212","authenticated-orcid":false,"given":"Marina","family":"Konopleva","sequence":"additional","affiliation":[{"name":"Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hagop","family":"Kantarjian","sequence":"additional","affiliation":[{"name":"Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2022,5,17]]},"reference":[{"issue":"15","key":"2022051715245510300_B1","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1182\/blood.2021011817","article-title":"Central nervous system involvement in blastic plasmacytoid dendritic cell neoplasm","volume":"138","author":"Pemmaraju","year":"2021","journal-title":"Blood."},{"issue":"2","key":"2022051715245510300_B2","doi-asserted-by":"crossref","first-page":"239","DOI":"10.3324\/haematol.2012.072645","article-title":"Blastic plasmacytoid dendritic cell neoplasm with leukemic presentation: an Italian multicenter study","volume":"98","author":"Pagano","year":"2013","journal-title":"Haematologica."},{"issue":"11","key":"2022051715245510300_B3","doi-asserted-by":"crossref","first-page":"3299","DOI":"10.1038\/s41375-021-01228-y","article-title":"Divergent clonal evolution of blastic plasmacytoid dendritic cell neoplasm and chronic myelomonocytic leukemia from a shared TET2-mutated origin","volume":"35","author":"Batta","year":"2021","journal-title":"Leukemia."},{"key":"2022051715245510300_B4","doi-asserted-by":"crossref","first-page":"2723","DOI":"10.1182\/blood-2019-132185","article-title":"Blastic plasmacytoid dendritic cell neoplasm (BPDCN) commonly presents in the setting of prior or concomitant hematologic malignancies (PCHM): patient characteristics and outcomes in the rapidly evolving modern targeted therapy era","volume":"134","author":"Pemmaraju","year":"2019","journal-title":"Blood."},{"issue":"1","key":"2022051715245510300_B5","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1080\/10428194.2021.1975192","article-title":"CD303 (BDCA-2)-a potential novel target for therapy in hematologic malignancies","volume":"63","author":"Wilson","year":"2022","journal-title":"Leuk Lymphoma."},{"issue":"10","key":"2022051715245510300_B6","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1097\/PAS.0000000000001316","article-title":"Dual expression of TCF4 and CD123 is highly sensitive and specific for blastic plasmacytoid dendritic cell neoplasm","volume":"43","author":"Sukswai","year":"2019","journal-title":"Am J Surg Pathol."},{"issue":"3","key":"2022051715245510300_B7","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.hoc.2020.01.002","article-title":"Molecular features of blastic plasmacytoid dendritic cell neoplasm: DNA mutations and epigenetics","volume":"34","author":"Sapienza","year":"2020","journal-title":"Hematol Oncol Clin North Am."},{"issue":"5","key":"2022051715245510300_B8","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1182\/blood.V99.5.1556","article-title":"Clinical and biologic features of CD4(+)CD56(+) malignancies","volume":"99","author":"Feuillard","year":"2002","journal-title":"Blood."},{"issue":"5","key":"2022051715245510300_B9","first-page":"8204","article-title":"Radiation therapy for cutaneous blastic plasmacytoid dendritic cell neoplasm: a case report and review of the literature","volume":"8","author":"Ishibashi","year":"2015","journal-title":"Int J Clin Exp Med."},{"issue":"4","key":"2022051715245510300_B10","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.jdcr.2017.03.015","article-title":"Localized skin-limited blastic plasmacytoid dendritic cell neoplasm: a subset with possible durable remission without transplantation","volume":"3","author":"Amitay-Laish","year":"2017","journal-title":"JAAD Case Rep."},{"issue":"7","key":"2022051715245510300_B11","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1097\/MPH.0000000000000964","article-title":"Pediatric blastic plasmacytoid dendritic cell neoplasm: a systematic literature review","volume":"39","author":"Kim","year":"2017","journal-title":"J Pediatr Hematol Oncol."},{"issue":"8","key":"2022051715245510300_B12","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1182\/blood.2019001144","article-title":"Multicenter analysis of outcomes in blastic plasmacytoid dendritic cell neoplasm offers a pretargeted therapy benchmark","volume":"134","author":"Taylor","year":"2019","journal-title":"Blood."},{"issue":"3","key":"2022051715245510300_B13","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.hoc.2020.01.011","article-title":"Chemotherapy options for blastic plasmacytoid dendritic cell neoplasm","volume":"34","author":"Haddadin","year":"2020","journal-title":"Hematol Oncol Clin North Am."},{"issue":"17","key":"2022051715245510300_B14","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1056\/NEJMoa1815105","article-title":"Tagraxofusp in blastic plasmacytoid dendritic-cell neoplasm","volume":"380","author":"Pemmaraju","year":"2019","journal-title":"N Engl J Med."},{"issue":"2","key":"2022051715245510300_B15","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1158\/2159-8290.CD-16-0999","article-title":"Blastic plasmacytoid dendritic cell neoplasm is dependent on BCL2 and sensitive to venetoclax","volume":"7","author":"Montero","year":"2017","journal-title":"Cancer Discov."},{"issue":"3","key":"2022051715245510300_B16","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1002\/ajh.25000","article-title":"Clinical experience with the BCL2-inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies","volume":"93","author":"DiNardo","year":"2018","journal-title":"Am J Hematol."},{"issue":"7","key":"2022051715245510300_B17","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1056\/NEJMc1814963","article-title":"More on blastic plasmacytoid dendritic-cell neoplasms","volume":"380","author":"Pemmaraju","year":"2019","journal-title":"N Engl J Med."},{"issue":"3","key":"2022051715245510300_B18","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1200\/JCO.2000.18.3.547","article-title":"Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia","volume":"18","author":"Kantarjian","year":"2000","journal-title":"J Clin Oncol."},{"issue":"5","key":"2022051715245510300_B19","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1002\/gcc.22831","article-title":"Whole-genome analysis uncovers recurrent IKZF1 inactivation and aberrant cell adhesion in blastic plasmacytoid dendritic cell neoplasm","volume":"59","author":"Bastidas Torres","year":"2020","journal-title":"Genes Chromosomes Cancer."},{"issue":"5","key":"2022051715245510300_B20","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1182\/bloodadvances.2020003359","article-title":"Transcriptomic and genomic heterogeneity in blastic plasmacytoid dendritic cell neoplasms: from ontogeny to oncogenesis","volume":"5","author":"Renosi","year":"2021","journal-title":"Blood Adv."},{"key":"2022051715245510300_B21","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.leukres.2018.01.013","article-title":"8q24\/MYC rearrangement is a recurrent cytogenetic abnormality in blastic plasmacytoid dendritic cell neoplasms","volume":"66","author":"Boddu","year":"2018","journal-title":"Leuk Res."},{"issue":"3","key":"2022051715245510300_B22","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1182\/blood-2012-08-448613","article-title":"Stem cell transplantation can provide durable disease control in blastic plasmacytoid dendritic cell neoplasm: a retrospective study from the European Group for Blood and Marrow Transplantation","volume":"121","author":"Roos-Weil","year":"2013","journal-title":"Blood."},{"issue":"23","key":"2022051715245510300_B23","doi-asserted-by":"crossref","first-page":"3559","DOI":"10.1182\/blood-2015-01-621268","article-title":"Long-term survival following autologous and allogeneic stem cell transplantation for blastic plasmacytoid dendritic cell neoplasm","volume":"125","author":"Aoki","year":"2015","journal-title":"Blood."},{"issue":"2","key":"2022051715245510300_B24","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1111\/bjh.14146","article-title":"Blastic plasmacytoid dendritic cell neoplasm: diagnostic criteria and therapeutical approaches","volume":"174","author":"Pagano","year":"2016","journal-title":"Br J Haematol."},{"issue":"3","key":"2022051715245510300_B25","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/j.hoc.2020.01.009","article-title":"Hematopoietic cell transplant for blastic plasmacytoid dendritic cell neoplasm","volume":"34","author":"Kharfan-Dabaja","year":"2020","journal-title":"Hematol Oncol Clin North Am."},{"issue":"9","key":"2022051715245510300_B26","first-page":"3433","article-title":"Relative hematopoietic stem cell transplantation for the treatment of blastic plasmacytoid dendritic cell neoplasm: a case report and literature review","volume":"12","author":"Niu","year":"2019","journal-title":"Int J Clin Exp Pathol."},{"issue":"2","key":"2022051715245510300_B27","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1097\/MOH.0000000000000569","article-title":"Blastic plasmacytoid dendritic cell neoplasm: diagnosis, manifestations, and treatment","volume":"27","author":"Sweet","year":"2020","journal-title":"Curr Opin Hematol."},{"issue":"9","key":"2022051715245510300_B28","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1080\/13543784.2018.1512970","article-title":"The advances in therapy of blastic plasmacytoid dendritic cell neoplasm","volume":"27","author":"Kerr","year":"2018","journal-title":"Expert Opin Investig Drugs."},{"issue":"5","key":"2022051715245510300_B29","first-page":"890","article-title":"Clinical features and treatment outcomes of blastic plasmacytoid dendritic cell neoplasm: a single-center experience in Korea","volume":"32","author":"Kim","year":"2017","journal-title":"Korean J Intern Med (Korean Assoc Intern Med)."},{"issue":"24","key":"2022051715245510300_B30","doi-asserted-by":"crossref","first-page":"4238","DOI":"10.1182\/bloodadvances.2019000647","article-title":"How should we diagnose and treat blastic plasmacytoid dendritic cell neoplasm patients?","volume":"3","author":"Garnache-Ottou","year":"2019","journal-title":"Blood Adv."},{"issue":"2","key":"2022051715245510300_B31","doi-asserted-by":"crossref","first-page":"e27","DOI":"10.1200\/JCO.2010.30.5441","article-title":"Blastic plasmacytoid dendritic cell neoplasm","volume":"29","author":"Chen","year":"2011","journal-title":"J Clin Oncol."},{"issue":"4","key":"2022051715245510300_B32","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1007\/s00277-018-3259-z","article-title":"Blastic plasmacytoid dendritic cell neoplasm: update on therapy especially novel agents","volume":"97","author":"Wang","year":"2018","journal-title":"Ann Hematol."},{"issue":"7","key":"2022051715245510300_B33","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1111\/jdv.16215","article-title":"Clinical diversity and treatment approaches to blastic plasmacytoid dendritic cell neoplasm: a retrospective multicentre study","volume":"34","author":"Br\u00fcggen","year":"2020","journal-title":"J Eur Acad Dermatol Venereol."},{"issue":"2","key":"2022051715245510300_B34","first-page":"150","article-title":"Successful treatment with biweekly CHOP for bone marrow relapse of blastic plasmacytoid dendritic cell neoplasm","volume":"58","author":"Ono","year":"2017","journal-title":"Rinsho Ketsueki."},{"key":"2022051715245510300_B35","first-page":"31","article-title":"Successful outcome of second allogeneic bone marrow transplantation for blastic plasmacytoid dendritic cell neoplasm with MYC locus rearrangement","volume":"11","author":"Kato","year":"2019","journal-title":"Leuk Res Rep."},{"issue":"10","key":"2022051715245510300_B36","doi-asserted-by":"crossref","first-page":"2341","DOI":"10.1080\/21645515.2020.1788299","article-title":"Targeting the alpha subunit of IL-3 receptor (CD123) in patients with acute leukemia","volume":"16","author":"Aldoss","year":"2020","journal-title":"Hum Vaccin Immunother."},{"issue":"1","key":"2022051715245510300_B37","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/2050-7771-2-4","article-title":"CD 123 is a membrane biomarker and a therapeutic target in hematologic malignancies","volume":"2","author":"Testa","year":"2014","journal-title":"Biomark Res."},{"issue":"9","key":"2022051715245510300_B38","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.3390\/cancers11091358","article-title":"CD123 as a therapeutic target in the treatment of hematological malignancies","volume":"11","author":"Testa","year":"2019","journal-title":"Cancers (Basel)."},{"issue":"11","key":"2022051715245510300_B39","doi-asserted-by":"crossref","first-page":"5005","DOI":"10.1172\/JCI128571","article-title":"DNA methyltransferase inhibition overcomes diphthamide pathway deficiencies underlying CD123-targeted treatment resistance","volume":"129","author":"Togami","year":"2019","journal-title":"J Clin Invest."},{"issue":"16","key":"2022051715245510300_B40","doi-asserted-by":"crossref","first-page":"4020","DOI":"10.1182\/bloodadvances.2019000173","article-title":"Approval of tagraxofusp-erzs for blastic plasmacytoid dendritic cell neoplasm","volume":"4","author":"Pemmaraju","year":"2020","journal-title":"Blood Adv."},{"key":"2022051715245510300_B41","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1182\/blood-2020-139903","article-title":"Clinical profile of IMGN632, a novel CD123-targeting antibody-drug conjugate (ADC), in patients with relapsed\/refractory (R\/R) blastic plasmacytoid dendritic cell neoplasm (BPDCN)","volume":"136","author":"Pemmaraju","year":"2020","journal-title":"Blood."},{"issue":"3","key":"2022051715245510300_B42","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.hoc.2020.01.006","article-title":"Immunotherapies targeting CD123 for blastic plasmacytoid dendritic cell neoplasm","volume":"34","author":"Xue","year":"2020","journal-title":"Hematol Oncol Clin North Am."},{"issue":"3","key":"2022051715245510300_B43","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.hoc.2020.01.007","article-title":"Novel therapies for blastic plasmacytoid dendritic cell neoplasm","volume":"34","author":"Lane","year":"2020","journal-title":"Hematol Oncol Clin North Am."},{"issue":"6","key":"2022051715245510300_B44","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1172\/JCI106069","article-title":"Drug effect in acute leukemia","volume":"48","author":"Lampkin","year":"1969","journal-title":"J Clin Invest."},{"issue":"22","key":"2022051715245510300_B45","doi-asserted-by":"crossref","first-page":"2158","DOI":"10.1056\/NEJMicm2003702","article-title":"Blastic plasmacytoid dendritic-cell neoplasm","volume":"383","author":"Gonzaga","year":"2020","journal-title":"N Engl J Med."},{"issue":"10","key":"2022051715245510300_B46","doi-asserted-by":"crossref","first-page":"2551","DOI":"10.1080\/10428194.2021.1919664","article-title":"Vindesine dexamethasone as a therapeutic option in elderly blastic plasmacytoid dendritic cell neoplasms: a monocentric experience","volume":"62","author":"Benarfa","year":"2021","journal-title":"Leuk Lymphoma."},{"issue":"1","key":"2022051715245510300_B47","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1182\/blood.V64.1.267.267","article-title":"Efficacy of daunorubicin in the therapy of adult acute lymphocytic leukemia: a prospective randomized trial by cancer and leukemia group B","volume":"64","author":"Gottlieb","year":"1984","journal-title":"Blood."},{"issue":"6","key":"2022051715245510300_B48","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1200\/JCO.1990.8.6.994","article-title":"Results of the vincristine, doxorubicin, and dexamethasone regimen in adults with standard- and high-risk acute lymphocytic leukemia","volume":"8","author":"Kantarjian","year":"1990","journal-title":"J Clin Oncol."},{"issue":"9","key":"2022051715245510300_B49","doi-asserted-by":"crossref","first-page":"10174","DOI":"10.18632\/oncotarget.7101","article-title":"Blastic plasmacytoid dendritic cell neoplasm frequently shows occult central nervous system involvement at diagnosis and benefits from intrathecal therapy","volume":"7","author":"Mart\u00edn-Mart\u00edn","year":"2016","journal-title":"Oncotarget."},{"issue":"14","key":"2022051715245510300_B50","doi-asserted-by":"crossref","first-page":"3435","DOI":"10.1182\/bloodadvances.2020001875","article-title":"Survival outcomes in blastic plasmacytoid dendritic cell neoplasm by first-line treatment and stem cell transplant","volume":"4","author":"Yun","year":"2020","journal-title":"Blood Adv."},{"issue":"1","key":"2022051715245510300_B51","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/s41409-021-01478-5","article-title":"Allogeneic hematopoietic cell transplantation for patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN)","volume":"57","author":"Bashir","year":"2022","journal-title":"Bone Marrow Transplant."},{"issue":"20","key":"2022051715245510300_B52","doi-asserted-by":"crossref","first-page":"4044","DOI":"10.1002\/cncr.31720","article-title":"Chemoimmunotherapy with inotuzumab ozogamicin combined with mini-hyper-CVD, with or without blinatumomab, is highly effective in patients with Philadelphia chromosome-negative acute lymphoblastic leukemia in first salvage","volume":"124","author":"Jabbour","year":"2018","journal-title":"Cancer."}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/6\/10\/3027\/1897666\/advancesadv2021006645.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/6\/10\/3027\/1897666\/advancesadv2021006645.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,17]],"date-time":"2022-05-17T12:57:40Z","timestamp":1652792260000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/6\/10\/3027\/483621\/Characteristics-and-outcomes-of-patients-with"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,17]]},"references-count":52,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2022,5,24]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2021006645","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,17]]}}}